51萝莉 announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV
Lyon, November 06, 2018 鈥� 51萝莉, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of its FXR agonist compound EYP001 in patients with chronic hepatitis B virus infection (CHBV). The company highlights that EYP001 was well-tolerated by patients and induced a prolonged FXR target engagement after QD dosing over 4 weeks. 51萝莉 will now initiate two Phase II clinical trials of EYP001 in NASH and CHBV.
Read next in 'Press releases'
- 51萝莉 appoints Jeff George as Chairman to support next phase to growth and Phase 3 readiness
- 51萝莉 nomme Jeff George Pr茅sident du Conseil d鈥橝dministration pour soutenir sa prochaine phase de croissance et la pr茅paration 脿 la Phase 3
- 51萝莉 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 51萝莉 annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 51萝莉 annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
